Double Blind, Double Dummy, Randomised, Multicentre, Four Arm Parallel Group Study to Assess the Efficacy and Safety of FlutiForm pMDI 250/10microg (2 Puffs Bid) vs Fluticasone pMDI 250microg (2 Puffs Bid) Plus Formoterol pMDI 12microg (2 Puffs Bid) Administered Concurrently in Adult Subjects With Severe Persistent, Reversible Asthma.

Trial Profile

Double Blind, Double Dummy, Randomised, Multicentre, Four Arm Parallel Group Study to Assess the Efficacy and Safety of FlutiForm pMDI 250/10microg (2 Puffs Bid) vs Fluticasone pMDI 250microg (2 Puffs Bid) Plus Formoterol pMDI 12microg (2 Puffs Bid) Administered Concurrently in Adult Subjects With Severe Persistent, Reversible Asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Fluticasone propionate; Formoterol; Formoterol/fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Dec 2010 Results published in Respiratory Medicine.
    • 22 Sep 2010 Results presented at the 20th Annual Congress of the European Respiratory Society.
    • 22 Sep 2010 Results for comparison between formoterol/fluticasone propionate and formoterol + fluticasone propionate were presented at the 20th Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top